Table 2 The frequency of symptoms in individuals with and without SARS-CoV-2-reactive IgG at the time of diagnosis and the time of symptom onset
From: Dynamics of anti-SARS-CoV-2 IgG antibodies post-COVID-19 in a Brazilian Amazon population
Symptoms | 1st IgG test | p* | ||
|---|---|---|---|---|
N | Reactive n = 125 n (%) | Nonreactive n = 10 n (%) | ||
Fever | 84 | 76 (60.8) | 7 (70.0) | 0.7405 |
Headache | 94 | 88 (70.4) | 6 (60.0) | 0.4911 |
Coryza | 62 | 59 (47.2) | 3 (30.0) | 0.3422 |
Cough | 85 | 79 (63.2) | 6 (60.0) | 0.9994 |
Sore throat | 73 | 66 (52.8) | 7 (70.0) | 0.3422 |
Body pain | 94 | 89 (71.2) | 5 (50.0) | 0.2818 |
Abdominal pain | 32 | 32 (25.6) | 0 (0.0) | 0.1165 |
Diarrhea | 62 | 58 (46.4) | 4 (40.0) | 0.7532 |
Vomiting | 16 | 16 (12.8) | 0 (0.0) | 0.3681 |
Nausea | 37 | 37 (29.6) | 0 (0.0) | 0.0614 |
Anosmia | 95 | 90 (72.0) | 5 (50.0) | 0.1640 |
Ageusia | 91 | 86 (68.8) | 5 (50.0) | 0.2939 |
Shortness of breath | 60 | 58 (46.4) | 2 (20.0) | 0.1843 |
Hair loss | 47 | 44 (35.2) | 3 (30.0) | 1.0000 |
Duration of symptoms | ||||
≤ 7 days | 43 | 40 (32.0) | 3 (30.0) | 1.0000 |
15 days | 43 | 39 (31.2) | 4 (40.0) | 0.7253 |
≥ 21 days | 46 | 44 (35.2) | 2 (20.0) | 0.4936 |
No symptoms | 03 | 2 (1.6) | 1 (10.0) | 0.2073 |